Diagnosis and treatment of gastroesophageal reflux disease in Ohio Medicaid patients: Practice patterns and temporal trends

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 1, 2004, Pages 21-27

  Cooper, Gregory S ^a,b   Mourand, William A ^a   Koroukian, Siran M ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gastroesophageal reflux; Gastrointestinal endoscopy; Histamine H2 antagonists; Medicaid; Porton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; AWARENESS; BARIUM ENEMA; BARRETT ESOPHAGUS; CASE MIX; CLINICAL PRACTICE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; ESOPHAGUS HEMORRHAGE; ESOPHAGUS MANOMETRY; ESOPHAGUS PH; ESOPHAGUS STRICTURE; ESOPHAGUS ULCER; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL RADIOGRAPHY; GASTROSCOPY; HEALTH CARE QUALITY; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTPATIENT CARE; PATIENT CARE; PEPTIC ULCER; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SEX DIFFERENCE; SOCIAL STATUS; UNITED STATES; UPPER GASTROINTESTINAL TRACT;

ADULT; AGED; COHORT STUDIES; ESOPHAGOSCOPY; FEMALE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MEDICAID; MIDDLE AGED; OHIO; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMPS; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS;

EID: 0742324807     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.818     Document Type: Article

References (22)

1. Dent J, Fendrick AM, Fennerty MB, et al. An evidence-based appraisal of reflux disease management - the Genval Workshop report. Gut 1999; 44: S1-S16.
2. Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276: 983-988.
3. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-1442.
4. Fennerty MB, Castell D, Fendrick AM, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment: suggested disease management guidelines. Arch Intern Med 1996; 156: 477-484.
5. Pope CE II. Acid-reflux disorders. N Engl J Med 1994; 331: 656-660.
6. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991; 151: 448-454.
7. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121: 1095-1100.
8. American Society for Gastrointestinal Endoscopy. The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract. Gastrointest Endosc 1998; 48: 663-668.
9. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF, Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991; 265: 1287-1289.
10. Pera M, Cameron AJ, Trastek VF, Carpenter HA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-513.
11. Chiba N, DeGara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-1810.
12. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-1110.
13. Jones MI, Greenfield SM, Jowett S, Bradley CP, Seal R. Proton pump inhibitors: a study of GPs' prescribing. Fam Pract 2001; 18: 333-338.
14. Fisher ES, Whaley FS, Krushat WM, et al. The accuracy of Medicare's hospital claims data: progress has been made, but problems remain. Am J Public Health 1992; 82: 243-248.
15. Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA. The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care 1999; 37: 436-444.
16. Cooper GS, Yuan Z, Stange KC, Dennis LK, Amini SB, Rimm AA. Agreement of Medicare claims and tumor registry data for assessment of cancer related treatment. Med Care 2000; 38: 411-421.
17. Cooper GS, Chak A, Lloyd LE, Hammar PJ, Harper DL, Rosenthal GE. The accuracy of diagnosis and procedural codes for patients with upper gastrointestinal hemorrhage. Gastrointest Endosc 2000; 51: 423-426.
18. Lessler JT, Harris BSH. Medicaid Data as a Source for Postmarketing Surveillance Information: Final Report. Research Triangle Institute: Research Triangle Park, NC, 1984.
19. Bashford JN, Norwood J, Chapman SR. Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database. BMJ 1998; 317: 452-456.
20. Lewis JD, Bilker WB, Brensinger C, Farrar JT, Strom BL. Hospitalization and mortality rates from peptic ulcer disease and gastrointestinal bleeding in the 1990s: relation to sales of NSAIDs and acid suppression medications. Am J Gastroenterol 2002; 97: 2540-2549.
21. Carson JL, Strom BL. Medicaid Databases. In Pharmacoepidemiology (2nd edn), Strom BL (ed.). John Wiley & Sons: Chichester, 1994; 199-216.
22. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs survey. J Clin Outcomes Management 2000; 7: 29-34.